Skip to main content

Table 5 Patients with stable disease (RECIST) for at least 4 cycles of treatment with dinaciclib

From: A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies

Subject number Diagnosis Dinaciclib dose level (mg/m2) Number of prior treatment regimens Response by RECIST Number of cycles
2902 NSCLC 0.66 16 SD 6
2910 Pseudomyxoma peritonei 2.59 3 SD 9
2913 Prostate cancer 3.63 2 SD 4
2920 Melanoma 3.63 3 SD 10
2926 Sarcoma 7.11 2 SD 12
2928 Gastrointestinal stromal tumor 7.11 2 SD 10
2931 Esophageal carcinoma 7.11 3 SD 11
2932 Adenoid cyst carcinoma 7.11 0 SD 5
2937 Adenoid cyst carcinoma 14.0 3 SD 8
2945 NSCLC 12.0 4 SD 4